Spöttl F, Froschauer J
Atherosclerosis. 1976 Nov-Dec;25(2-3):293-301. doi: 10.1016/0021-9150(76)90034-4.
The effect of Etofibrate, a chemical compound of the two antihyperlipidemic agents Clofibrate and nicotinic acid, on elevated plasma fibrinogen and plasminogen concentrations was investigated in a 6 months' survey in 25 patients with different types of primary hyperlipidemia. A consistent reduction of fibrinogen levels to normal occurred after 6 months' therapy, whereas the effect on plasminogen concentrations was weaker and not significant. The fibrinogen-lowering effect of Etofibrate was not related to the pretreatment levels but nearly equal in all cases. The possible consequences on the hemostatic system are discussed. On account of the low daily dosage, apart from a slight flush, no side-effects were noted.
益多酯(一种由两种降血脂药物氯贝丁酯和烟酸组成的化合物)对25例不同类型原发性高脂血症患者进行了为期6个月的研究,以探讨其对血浆纤维蛋白原和纤溶酶原浓度升高的影响。经过6个月的治疗,纤维蛋白原水平持续降低至正常,而对纤溶酶原浓度的影响较弱且不显著。益多酯降低纤维蛋白原的作用与治疗前水平无关,在所有病例中几乎相同。文中讨论了其对止血系统可能产生的后果。由于每日剂量较低,除轻微脸红外,未观察到副作用。